Dixon Hubard Feinour & Brown Inc. VA Acquires 11,195 Shares of ICU Medical, Inc. (ICUI)

Dixon Hubard Feinour & Brown Inc. VA boosted its position in ICU Medical, Inc. (NASDAQ:ICUI) by 300.5% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,920 shares of the medical instruments supplier’s stock after buying an additional 11,195 shares during the period. Dixon Hubard Feinour & Brown Inc. VA owned about 0.08% of ICU Medical worth $2,574,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ICUI. Creative Planning boosted its stake in ICU Medical by 315.6% in the first quarter. Creative Planning now owns 665 shares of the medical instruments supplier’s stock worth $102,000 after buying an additional 505 shares during the period. Ameritas Investment Partners Inc. purchased a new stake in ICU Medical during the first quarter worth approximately $194,000. Sawgrass Asset Management LLC purchased a new stake in ICU Medical during the first quarter worth approximately $229,000. Janney Montgomery Scott LLC boosted its stake in ICU Medical by 0.4% in the first quarter. Janney Montgomery Scott LLC now owns 1,607 shares of the medical instruments supplier’s stock worth $245,000 after buying an additional 7 shares during the period. Finally, State of Alaska Department of Revenue boosted its stake in ICU Medical by 2.5% in the first quarter. State of Alaska Department of Revenue now owns 1,640 shares of the medical instruments supplier’s stock worth $250,000 after buying an additional 40 shares during the period. Institutional investors and hedge funds own 77.85% of the company’s stock.

Shares of ICU Medical, Inc. (NASDAQ:ICUI) opened at 164.90 on Friday. The firm has a 50-day moving average price of $172.11 and a 200-day moving average price of $158.73. ICU Medical, Inc. has a one year low of $120.15 and a one year high of $176.50. The stock has a market cap of $3.27 billion, a price-to-earnings ratio of 66.04 and a beta of 0.37.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.58 by $0.06. ICU Medical had a return on equity of 8.27% and a net margin of 6.10%. The firm had revenue of $331.51 million for the quarter, compared to the consensus estimate of $318.30 million. During the same period last year, the company posted $1.15 earnings per share. The business’s revenue was up 242.8% compared to the same quarter last year. Analysts anticipate that ICU Medical, Inc. will post $4.14 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.com-unik.info/2017/08/12/dixon-hubard-feinour-brown-inc-va-has-2-57-million-stake-in-icu-medical-inc-icui-updated-updated-updated.html.

Several brokerages recently issued reports on ICUI. Zacks Investment Research cut ICU Medical from a “buy” rating to a “hold” rating in a research report on Friday, July 14th. Sidoti cut ICU Medical from a “buy” rating to a “neutral” rating in a research report on Tuesday, June 20th. BidaskClub cut ICU Medical from a “hold” rating to a “sell” rating in a research report on Wednesday. Roth Capital cut ICU Medical from a “buy” rating to a “neutral” rating in a research report on Thursday, May 11th. They noted that the move was a valuation call. Finally, Gabelli restated a “buy” rating on shares of ICU Medical in a research report on Friday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. ICU Medical presently has a consensus rating of “Hold” and a consensus price target of $193.00.

In other news, Chairman Vivek Jain sold 100,000 shares of the stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $170.80, for a total value of $17,080,000.00. Following the transaction, the chairman now directly owns 110,925 shares of the company’s stock, valued at $18,945,990. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joseph R. Saucedo sold 4,500 shares of the stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $162.51, for a total transaction of $731,295.00. Following the completion of the transaction, the director now directly owns 3,091 shares in the company, valued at $502,318.41. The disclosure for this sale can be found here. Insiders have sold 227,349 shares of company stock worth $38,623,370 over the last ninety days. Insiders own 15.90% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Institutional Ownership by Quarter for ICU Medical (NASDAQ:ICUI)

What are top analysts saying about ICU Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ICU Medical Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit